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SCIENTIFIC EDITORIAL
Silent myocardial ischaemia. To screen or not to
screen? That is. . .
Ischémie myocardique silencieuse. Dépister ou ne pas dépister ?
Telle est la question
Paul Valensi
Department of Endocrinology-Diabetology-Nutrition, Paris-Nord University,
Jean-Verdier Hospital, AP—HP, avenue du 14-Juillet, 93143 Bondy cedex, FranceKEYWORDS
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MOTS CLÉS
Ichémie myocardique
Coronary artery disease occurs more frequently and is more severe in diabetic patients.
Some studies suggest that the cardiovascular prognosis of diabetic patients without known
coronary disease is as poor as that for non-diabetic patients with known coronary dis-
ease, which has led to the suggestion that diabetes should be considered a ‘coronary
heart disease equivalent’ [1]. In fact, many diabetic patients live with signiﬁcant coronary
lesions without experiencing the signs or symptoms of coronary artery disease. As a conse-
quence, it appears logical to detect coronary artery disease at the silent stage to enable the
prevention of cardiac events. A number of studies have shown clearly that silent myocar-
dial ischaemia (SMI) — as evidenced by non-invasive tests such as the electrocardiogram
stress test, myocardial scintiscan or stress echocardiography— affects 20—50% of diabetic
patients with additional risk factors, and that 40—90% of patients with SMI have signiﬁcant
coronary stenoses on angiography [2]. Moreover, the predictive value of SMI for coronarysilencieuse ;
Maladie des artères
coronaires ;
Diabète
events is well established, particularly if SMI is associated with coronary stenoses [3,4].
Recently, a controversy has emerged about the usefulness of screening diabetic patients
for SMI [5—7]. This controversy is based on several arguments. The ﬁrst concerns feasibility,
as the number of diabetic patients with other risk factors is huge and screening tests
cannot be performed in them all. The cost-effectiveness ratio has also been questioned;
Abbreviation: SMI, Silent myocardial ischaemia.
 Intensive cardiovascular risk factors therapy and prevalence of silent myocardial ischaemia in patients with type 2 diabetes,
Barthelemy O., Jacqueminet S., Rouzet F., Isnard R., Bouzamondo A., Le Guludec D., Grimaldi A., Metzger J.P., Le Feuvre C.,
doi:10.1016/j.acvd.2008.06.015.
E-mail address: paul.valensi@jvr.aphp.fr.
1875-2136/$ — see front matter © 2008 Elsevier Masson SAS. All rights reserved.
doi:10.1016/j.acvd.2008.10.001
5c
s
n
g
p
t
p
d
1
s
m
c
t
d
t
t
r
b
s
m
r
f
t
r
p
a
c
[
m
o
t
c
F
r
ﬁ
f
t
r
D
p
i
b
f
v
[
1
T
a
f
d
w
a
d
c
m
t
e
a
c
(
s
d
s
l
t
i
f
w
c
a
t
p
t
o
t
t
s
W
a
2
m
b
c
p
t
t
l
i
S
b
m
a
r
w
e
a
w
ﬁ
o
b
a
s
b
c
h
t
v
o
r
a
o
b
m10
oronary revascularization is performed in very few patients
creened for SMI and the beneﬁt of revascularization is
ot established clearly. Another line of argument has been
enerated by the marked improvement in cardiovascular
rognosis due to the intensiﬁcation of preventive medical
reatments. Indeed, the rates of coronary events in the
lacebo arms of major randomized studies that included
iabetic patients have decreased by over 50% since the
990’s [8—10]. Moreover, a multifactorial approach targeting
everal risk factors is more effective than unifactorial treat-
ent, as shown in the Steno-2 study [11]. Compared with
onventional management, an intensiﬁed approach applied
o high-risk type 2 diabetic patients reduced the rate of car-
iovascular and microangiopathic complications by 50%, and
he beneﬁt remained signiﬁcant 10 years after the end of
he randomized period [11]. Based on these data, the cur-
ent guidelines have deﬁned lower targets for blood glucose,
lood pressure and blood lipid concentrations and stand
trongly in favour of intensiﬁcation of preventive treat-
ents.
While it may be attractive to consider that the accu-
ate treatment of all risk factors will render screening
or coronary disease unnecessary, there are several limita-
ions to this theory. The multifactorial intensive strategy
equires training of doctors and healthcare providers, and
atient education and coaching. In addition, when using this
pproach, the targets — in particular those for blood glu-
ose and blood pressure— are achieved in very few patients
11]. Furthermore, changes in clinical practice are slow to
aterialize in real life, as shown by the European Action
n Secondary and Primary prevention through Intervention
o Reduce Events (EUROASPIRE) studies [12], and patient
ompliance with multiple treatments is difﬁcult to obtain.
inally, in the Steno-2 study, the residual cardiovascular risk
emained high, which could be due to late treatment intensi-
cation, insufﬁcient intensiﬁcation or possibly unknown risk
actors. More potent intensiﬁcation could be dangerous due
o the risk of severe hypoglycaemic events, as suggested
ecently by the Action to Control Cardiovascular Risk in
iabetes (ACCORD) study, this risk being higher in elderly
atients [13].
In the future, in line with recent guidelines, treatment
ntensiﬁcation should be started earlier, at the onset of dia-
etes or even in prediabetic stages, to increase the potential
or controlling blood pressure more efﬁciently and to pre-
ent diabetic complications more effectively.
In the current issue of this journal, Barthélémy et al.
14] report their results on SMI screening in a series of
22 patients who were treated intensively before inclusion.
he control of blood glucose, lipids and blood pressure
t inclusion was rather good, albeit not at the targets
or greater than 50% of the patients, which conﬁrms the
ifﬁculty in reaching all of these goals. Most of the patients
ere receiving blockers of the renin-angiotensin system
nd around 50% were receiving antiplatelet therapy (no
ata were reported on statin treatment). The authors
onsidered these patients to be at high risk. In fact, the
ajor risk factors were present in a low proportion of
hese patients: 32% had microalbuminuria and 12% had
vidence of peripheral artery disease, whereas obesity
nd retinopathy were taken as risk factors, which is not
onsensual. As expected, the prevalence of SMI was low
p
l
t
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16%) and only seven patients had signiﬁcant coronary
tenoses. The rate of cardiac events after a mean follow-up
uration of 2 years was very low (0.8% per year).
The prevalence of SMI was lower than in many previous
tudies that included higher-risk patients [2], and was also
ower than in the authors’ previous report [15]; they suggest
hat the most likely reason for the difference is treatment
ntensiﬁcation before inclusion. In fact, it may also result
rom the inclusion criteria and assessment methods, as SMI
as detected by two functional tests in their previous work
ompared with only one in the present paper. The authors
lso suggest that the low cardiac event rate, particularly
he lack of events in the patients with SMI, may result from
revious intensive treatment and coronary revasculariza-
ion. The latter factor was probably the most important
ne, in addition to more intensive medical treatments in
he patients with SMI (which could not be documented).
We reported recently some data obtained from a popula-
ion of 781 diabetic patients whom we have screened for SMI
ince 1992, always using stress myocardial scintigraphy [16].
hen we compared the results in those screened before
nd after 2000, it appeared that the patients screened since
000 had a higher-risk proﬁle (more patients with microalbu-
inuria and more hypertensives). SMI prevalence was similar
efore and after 2000 but the percentage of patients with
oronary stenoses on angiography was lower after 2000,
ossibly due to the recent medical treatment intensiﬁca-
ion recommended in practice guidelines. Interestingly, in
he group of patients included after 2000, no cardiovascu-
ar event occurred after a mean 3-year follow-up period
n the patients free of SMI, whereas in the patients with
MI, the prognosis was as severe as in the group included
efore 2000. This suggests that SMI still warrants speciﬁc
anagement and coronary revascularization when appropri-
te, in addition to risk factor correction. Similarly, a recent
andomized study that included 141 asymptomatic patients
ith type 2 diabetes has shown that the rate of cardiac
vents was signiﬁcantly lower in patients screened for SMI
nd revascularized when necessary than in patients who
ere not screened [17]. This observation needs to be con-
rmed in other randomized studies involving larger numbers
f patients.
In conclusion, it is not yet time to stop screening dia-
etic patients for SMI. Such a scenario can be foreseen at
stage when all risk factors are treated very early, inten-
ively and long term. In the meantime, screening should
e continued but the strategy needs to be improved. The
urrent French guidelines [18] recommend the screening of
igh-risk patients. In order to reduce the number of patients
hat have to be screened, increase the positive predictive
alue of non-invasive tests and detect the highest number
f patients with silent coronary stenoses who need to be
evascularized, non-invasive tests should be performed in
subset of patients with the greatest a priori probability
f having coronary stenoses. The selection criteria ought to
e changed as the traditional risk factors are poor deter-
inants of SMI and silent stenoses, and more and more
atients are treated with statins even if they don’t have
ipid disorders, and by blockers of the renin-angiotensin sys-
em without being hypertensive. The new criteria might
e based on ‘new’ risk factors or risk integrators such as
oronary artery calciﬁcations, artery stiffness or endothelial
t is.
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[Silent myocardial ischaemia. To screen or not to screen? Tha
dysfunction, or biomarkers may be used [2]. Some of these
explorations could be used as a ﬁrst step before carrying out
the functional test for ischaemia. Whether this strategy will
improve the risk:beneﬁt ratio of SMI screening needs to be
evaluated in further research.
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